| 纯度 | >85%SDS-PAGE. |
| 种属 | Human |
| 靶点 | TPM3 |
| Uniprot No | P06753 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 2-285aa |
| 氨基酸序列 | MEAIKKKMQMLKLDKENALDRAEQAEAEQKQAEERSKQLEDELAAMQKKLKGTEDELDKYSEALKDAQEKLELAEKKAADAEAEVASLNRRIQLVEEELDRAQERLATALQKLEEAEKAADESERGMKVIENRALKDEEKMELQEIQLKEAKHIAEEADRKYEEVARKLVIIEGDLERTEERAELAESKCSELEEELKNVTNNLKSLEAQAEKYSQKEDKYEEEIKILTDKLKEAETRAEFAERSVAKLEKTIDDLEDELYAQKLKYKAISEELDHALNDMTSI |
| 预测分子量 | 59.8kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于TPM3重组蛋白的模拟参考文献示例(非真实文献，仅供格式参考)：
---
1. **文献名称**: "Recombinant TPM3 expression and its role in cytoskeletal dynamics"
**作者**: Smith A, et al.
**摘要**: 研究利用大肠杆菌系统表达重组TPM3蛋白，分析其与肌动蛋白结合的特性，并发现TPM3通过调节微丝稳定性影响细胞迁移能力。
---
2. **文献名称**: "Structural characterization of TPM3 isoforms in cancer progression"
**作者**: Johnson R, et al.
**摘要**: 通过X射线晶体学解析重组TPM3蛋白的两种亚型结构，揭示其构象差异如何影响肿瘤细胞侵袭性及耐药性相关信号通路。
---
3. **文献名称**: "Functional interaction of recombinant TPM3 with ALK kinase in pediatric cancers"
**作者**: Lee H, et al.
**摘要**: 体外实验证明重组TPM3与间变性淋巴瘤激酶(ALK)直接结合，阐明了TPM3-ALK融合蛋白在儿童神经母细胞瘤中的致癌机制。
---
4. **文献名称**: "TPM3 recombinant protein as a biomarker for muscle disorders"
**作者**: Garcia M, et al.
**摘要**: 开发基于重组TPM3的ELISA检测方法，发现其在先天性肌病患者的血清中异常表达，为疾病诊断提供潜在生物标志物。
---
注：以上文献为虚构示例，实际研究需通过PubMed、Web of Science等数据库检索真实文献。
**Background of TPM3 Recombinant Protein**
TPM3 (Tropomyosin 3) is a member of the tropomyosin family, a group of actin-binding proteins critical for regulating cytoskeletal dynamics and muscle contraction. Encoded by the *TPM3* gene, this protein exists in multiple isoforms due to alternative splicing, enabling functional diversity in various tissues. TPM3 is primarily expressed in skeletal muscle and non-muscle cells, where it stabilizes actin filaments, modulates their interactions with myosin, and influences cell shape, motility, and intracellular transport.
Recombinant TPM3 protein is engineered using biotechnological methods, often expressed in systems like *E. coli* or mammalian cells to ensure proper folding and post-translational modifications. This allows researchers to study its structure-function relationships, interactions with binding partners (e.g., actin, tropomodulin), and regulatory roles in cellular processes. TPM3 dysfunction is linked to diseases such as congenital myopathies (e.g., nemaline myopathy) and certain cancers, where aberrant expression or mutations disrupt cytoskeletal integrity, leading to muscle weakness or tumor progression.
In research, recombinant TPM3 serves as a tool to investigate pathogenic mechanisms, screen therapeutic compounds, or develop diagnostic assays. Its coiled-coil structure, comprising ~284 amino acids, is a focus for structural studies to elucidate mechanisms of actin filament regulation. Additionally, TPM3’s role in cancer cell invasion and metastasis highlights its potential as a biomarker or therapeutic target. By leveraging recombinant TPM3. scientists aim to unravel its physiological and pathological contributions, advancing insights into cytoskeletal biology and precision medicine strategies.
×
